309 related articles for article (PubMed ID: 32619407)
1. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity.
Mender I; Zhang A; Ren Z; Han C; Deng Y; Siteni S; Li H; Zhu J; Vemula A; Shay JW; Fu YX
Cancer Cell; 2020 Sep; 38(3):400-411.e6. PubMed ID: 32619407
[TBL] [Abstract][Full Text] [Related]
2. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
[TBL] [Abstract][Full Text] [Related]
3. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway.
Guo E; Xiao R; Wu Y; Lu F; Liu C; Yang B; Li X; Fu Y; Wang Z; Li Y; Huang Y; Li F; Wu X; You L; Qin T; Lu Y; Huang X; Ma D; Mills GB; Sun C; Chen G
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34825915
[TBL] [Abstract][Full Text] [Related]
4. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
[TBL] [Abstract][Full Text] [Related]
5. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
Zhang G; Wu LW; Mender I; Barzily-Rokni M; Hammond MR; Ope O; Cheng C; Vasilopoulos T; Randell S; Sadek N; Beroard A; Xiao M; Tian T; Tan J; Saeed U; Sugarman E; Krepler C; Brafford P; Sproesser K; Murugan S; Somasundaram R; Garman B; Wubbenhorst B; Woo J; Yin X; Liu Q; Frederick DT; Miao B; Xu W; Karakousis GC; Xu X; Schuchter LM; Mitchell TC; Kwong LN; Amaravadi RK; Lu Y; Boland GM; Wei Z; Nathanson K; Herbig U; Mills GB; Flaherty KT; Herlyn M; Shay JW
Clin Cancer Res; 2018 Oct; 24(19):4771-4784. PubMed ID: 29563139
[No Abstract] [Full Text] [Related]
6. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
7. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.
Eglenen-Polat B; Kowash RR; Huang HC; Siteni S; Zhu M; Chen K; Bender ME; Mender I; Stastny V; Drapkin BJ; Raj P; Minna JD; Xu L; Shay JW; Akbay EA
Nat Commun; 2024 Jan; 15(1):672. PubMed ID: 38253555
[TBL] [Abstract][Full Text] [Related]
8. Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma.
Mender I; Siteni S; Barron S; Flusche AM; Kubota N; Yu C; Cornelius C; Tedone E; Maziveyi M; Grichuk A; Venkateswaran N; Conacci-Sorrell M; Hoshida Y; Kang R; Tang D; Gryaznov S; Shay JW
Mol Cancer Ther; 2023 Jun; 22(6):737-750. PubMed ID: 37070671
[TBL] [Abstract][Full Text] [Related]
9.
Mender I; Batten K; Peyton M; Vemula A; Cornelius C; Girard L; Gao B; Minna JD; Shay JW
Cancer Res; 2020 Mar; 80(5):929-936. PubMed ID: 31948943
[TBL] [Abstract][Full Text] [Related]
10. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Li X; Liu Z; Zhang A; Han C; Shen A; Jiang L; Boothman DA; Qiao J; Wang Y; Huang X; Fu YX
Nat Commun; 2019 Jul; 10(1):3251. PubMed ID: 31324798
[TBL] [Abstract][Full Text] [Related]
11. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
12. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
13. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
[TBL] [Abstract][Full Text] [Related]
14. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8
Turley JL; Ward RW; Huete-Carrasco J; Muñoz-Wolf N; Roche K; Jin L; Bowie A; Andersson M; Lavelle EC
Cell Rep Med; 2024 May; 5(5):101560. PubMed ID: 38729159
[TBL] [Abstract][Full Text] [Related]
16. Turning telomerase into a Jekyll and Hyde case?
Wellinger RJ
Cancer Discov; 2015 Jan; 5(1):19-21. PubMed ID: 25583799
[TBL] [Abstract][Full Text] [Related]
17. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
18. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.
Mender I; LaRanger R; Luitel K; Peyton M; Girard L; Lai TP; Batten K; Cornelius C; Dalvi MP; Ramirez M; Du W; Wu LF; Altschuler SJ; Brekken R; Martinez ED; Minna JD; Wright WE; Shay JW
Neoplasia; 2018 Aug; 20(8):826-837. PubMed ID: 30015158
[TBL] [Abstract][Full Text] [Related]
19. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
20. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
